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Abstract
Background: Differences in HLA allele frequencies between the diseased and healthy populations
may signify efficient immune responses, a notion that has been successfully tested for infectious
diseases or for association with genetic elements involved in a distinct type of immunity. This
retrospective study is intended to detect differences in MHC class I carrier frequencies of advanced
melanoma patients compared to healthy bone marrow donors.
Methods: The HLA-A and -B carrier frequencies of 748 stage IV melanoma patients retrieved
from serotyping at 6 different centers in Germany were compared using a chi-square test to 13,386
fully HLA typed bone marrow donors registered in the German national bone marrow donor
registry.
Results: The comparison of HLA carrier frequencies in advanced cancer patients with healthy
bone marrow donors revealed a significant decrease in HLA-B8 carrier frequencies, which was also
apparent in patients with advanced disease compared to patients with loco-regional disease.
Conclusion: The data suggest that protective immune responses restricted to distinct MHC class
I molecules may be operational in a subset of melanoma patients, which is the prerequisite for a
large scale screen for the corresponding epitopes. Alternatively, the known association of the
ancestral haplotype HLA-A1, -B8 and -DR3 with genetic elements such as distinct TNF-α alleles
might have a protective effect on disease progression. In any case, identification of the cause of
protection within this patient subset might lead to a significant improvement in the efficacy of
current immunotherapeutic approaches.
Background
Active immunization against solid tumors is amongst the
most promising therapeutic approaches for such diseases.
Different immunization schedules are currently being
explored in numerous clinical trials, including vaccina-
tion with MHC class I restricted T-cell epitopes derived
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from tumor associated antigens (TAA) [1]. To date, onco-
genes have been intensively studied as targets for immu-
notherapy to minimize the risk of immune escape. As an
example, we have recently identified B-Raf V600E (previ-
ously designated B-Raf V599E) as a potential TAA for
immunotherapies against melanoma [2,3]. The tumor
antigens deployed are characterized by their ability to
elicit immune responses in patients, and the choice of
peptide epitopes derived from these antigens is mainly
dictated by the frequency of HLA alleles in the normal
population [4]. However, this strategy for identifying tar-
gets for therapy might actually miss the most valuable
epitopes.
As early as 1991, it was proposed that disease-associated
imbalances in HLA allele frequencies between diseased
and healthy populations may signify efficient immune
responses [5]. Although this approach was successfully
adapted for the malaria system [6], transfer to cancer
research has not yet been envisioned. In theory, any
epitope derived from TAA that elicits an effective immune
response able to eradicate the tumor should impact on the
frequency of the respective HLA allele in this patient pop-
ulation. Assuming that the antigen is reasonably common
within the patient cohort, the frequency of the HLA allele
in the context of which the epitope is presented should be
substantially reduced in patients with progressive disease,
i.e. those who failed to mount an effective immune
response. In practice, it is difficult to validate this edifice
of ideas, as several prerequisites usually remain unknown:
(i) the nature and (ii) the grade of expression of the corre-
sponding TAA, and (iii) the percentage of patients mount-
ing a protective immune response against this antigen.
The fact that the HLA phenotype is known for a large
number of patients suffering from advanced stages of
immunogenic tumors such as melanoma allows at least
one consequence of this intellectual experiment to be ver-
ified or falsified: viz., whether the frequency of certain
HLA class I alleles is reduced in patients in whom the
immune system failed to control the disease.
However, HLA imbalances can also be explained by link-
age to genetic factors influencing disease progression. In
this respect, it should be noted that many non-MHC genes
encoding immunologically relevant molecules such as
TNF-α or components of the complement system are
located in the HLA locus, and that some alleles of these
non-MHC genes are genetically linked to certain HLA alle-
les.
Methods
Data acquisition and HLA serotyping
The results of the serological HLA-A and -B typing of 748
AJCC stage IV melanoma patients performed in the Uni-
versity Hospitals of Erlangen (267 patients), Berlin (217
patients), Würzburg (141 patients), Mannheim (82
patients), Mainz (26 patients) and Münster (15 patients)
were collected. To compare stage I-III with stage IV
patients, the serotyping of 302 stage I-III patients per-
formed in Berlin was also taken into account. The scien-
tific workup of the HLA phenotyping results was approved
by the local ethics committees, provided the patient gave
informed consent.
Data comparison and statistical analysis
The data compiled from this patient cohort were com-
pared to those from 13,386 fully HLA-typed bone marrow
donors registered in the German national bone marrow
donor registry [7]. Data analysis was performed using the
Graph Pad Prism software package and MS Excel 2003.
Stage IV patients were compared to healthy bone marrow
donors using a two sided chi-square test; stage I-III
patients were compared to stage IV patients from Berlin,
and to the whole cohort, using a two sided Fisher's exact
test. An observation was regarded as significant if p < 0.01.
The ratio between stage IV and stage I-III carrier frequen-
cies was calculated to compare the relative decrease
between different HLA alleles; the mean ratio comprises
all HLA alleles with carrier frequencies above 15% (n =
11) +/- standard deviation.
Results and discussion
Table 1 summarizes the HLA frequencies for MHC class I
alleles of the HLA-A, HLA-B and HLA-C loci in stage IV
melanoma patients. Frequencies are given for all alleles
that have been typed. If subtypes (depicted in italics) were
determined, the main type (depicted in bold) contains the
cumulative carrier frequencies and the percentage of sub-
types is given. Because HLA-C was only phenotyped in
approximately half the patients, only the HLA-A and -B
carrier frequencies were compared to healthy blood
donors, and we restricted our analysis to HLA alleles with
carrier frequencies above 4.5% (table 2). Subtypes were
compared if more than 90% of the corresponding allele
were subtyped in both groups. While no significant varia-
tion between the two groups was evident for most alleles,
the frequency of HLA-B8 exhibited a significant decrease
from 20.3% in bone marrow donors to 16.2% in
melanoma patients (P = 0.0079, two-sided chi square
test). In addition, HLA-B35 and HLA-A26 showed a non-
significant tendency towards lower carrier frequencies
(HLA-B35 from 18.5% to 15.2%; P = 0.027, and HLA-A26
from 6.98% to 5.01%; P = 0.039). The statistical analysis
was performed using a two sided chi-square test and P val-
ues below 0.01 were regarded as statistically significant.
The lower P value was chosen to avoid type I errors due to
multiallele comparison, according to the suggestion by
Svejgaard and Ryder [8]. In contrast, a Bonferroni correc-
tion for an hypothesis-generating approach in a retrospec-BMC Medicine 2006, 4:5 http://www.biomedcentral.com/1741-7015/4/5
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tive study like this, with no a priori hypothesis for a
specific association, is not indicated [9].
To analyze sufficient numbers of stage IV melanoma
patients, we pooled data sets from different dermatology
departments throughout Germany. Although this
approach has the advantage of minimizing the likelihood
of systematic errors from the data acquisition process, it
would be still of interest to compare data sets derived
from the same center. This would also help to overcome
the necessity to compare stage IV melanoma patients with
healthy bone marrow donors, with no further informa-
tion on parameters such as skin type or ethnic back-
ground, by using the more appropriate control of early
disease patients. Consequently, in one center, additional
HLA data were acquired from stage I-III melanoma
patients. Thus, it was possible to compare HLA-A and -B
carrier frequencies of patients with loco-regional disease
(n = 302 HLA-A, n = 301 HLA-B) with those of dissemi-
nated melanoma (n = 214 HLA-A, n = 215 HLA-B). As
depicted in Fig. 1, stage IV patients are again characterized
by a decrease in carrier frequencies for HLA-A26, HLA-B8
and HLA-B35, whereas the means of the other HLA alleles
remain stable. The difference is in the same range as that
observed when the initial cohort of stage IV patients was
compared with healthy bone marrow donors. It should be
noted, however, that the observed reduction was not sta-
tistically significant for either HLA-B8 (stage I-III: 20.93%,
stage IV: 17.67%, P = 0.37 two sided Fisher's exact test),
HLA-B35 (stage I-III: 19.27%, stage IV: 14.42%, P = 0.16)
or HLA-A26 (stage I-III: 7.28%, stage IV: 5.61%, P = 0.48),
mainly because of the small number of patients included
Table 1: HLA-A, -B and -C carrier frequencies of stage IV melanoma patients. HLA-A and B alleles of 739 and 709 stage IV melanoma 
patients were typed serologically; HLA-C (391 stage IV melanoma patients) was typed by PCR. The frequencies of all alleles included 
in the analysis are shown. Subtypes are given in italics; the main types that have been partially subtyped are shown in bold. HLA carrier 
frequencies of the main types that have been partially subtyped encompass the carrier frequencies of the subtypes; the fraction of 
patients who have been subtyped for a certain allele is given as a percentage.
HLA-A (n = 739) HLA-B (n = 709) HLA-C (n = 391)
serotype frequency subtyped serotype frequency subtyped allele frequency
HLA-A1 28.69% HLA-B5 12.55% 89.89% HLA-Cw1 5.88%
HLA-A2 51.42% HLA-B51 10.30% HLA-Cw2 12.53%
HLA-A3 28.96% HLA-B52 0.99% HLA-Cw3 23.02%
HLA-A9 23.68% 99.43% HLA-B7 27.79% HLA-Cw4 23.53%
HLA-A23 5.41% HLA-B8 16.22% HLA-Cw5 12.79%
HLA-A24 18.13% HLA-B12 24.96% 98.31% HLA-Cw6 23.27%
HLA-A10 11.23% 98.80% HLA-B44 23.41% HLA-Cw7 48.34%
HLA-A25 5.55% HLA-B45 1.13% HLA-Cw8 3.07%
HLA-A26 5.01% HLA-B13 5.64%
HLA-A34 0.14% HLA-B14 4.80% 29.41%
HLA-A66 0.41% HLA-B64 0.28%
HLA-A11 9.34% HLA-B65 1.13%
HLA-A19 22.46% 96.99% HLA-B15 14.10% 79.00%
HLA-A29 5.82% HLA-B62 10.58%
HLA-A30 2.98% HLA-B63 0.56%
HLA-A31 5.14% HLA-B75 0.00%
HLA-A32 5.55% HLA-B16 9.59% 98.53%
HLA-A33 2.30% HLA-B38 4.94%
HLA-A28 6.63% 36.73% HLA-B39 4.51%
HLA-A68 2.03% HLA-B18 10.58%
HLA-A69 0.41% HLA-B21 4.65% 96.97%
HLA-B49 2.26%
HLA-B50 2.26%
HLA-B22 3.24% 95.65%
HLA-B54 0.14%
HLA-B55 1.41%
HLA-B56 1.55%
HLA-B27 8.89%
HLA-B35 15.23%
HLA-B37 3.95%
HLA-B40 11.99% 90.59%
HLA-B60 8.46%
HLA-B61 2.40%
HLA-B41 2.96%BMC Medicine 2006, 4:5 http://www.biomedcentral.com/1741-7015/4/5
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in this analysis, leading to a low statistical power. How-
ever, differences in ethnic background within the
melanoma patient and bone marrow donor groups might
still be a concern. Indeed, the 8.1 ancestral haplotype (8.1
AH) encompassing the alleles HLA-A1, -B8 and DR3 is
much more frequent in the Caucasian population than in
other ethnic groups. As an example, Cao et al. compared
the HLA frequencies of the five major ethnic groups in the
US population [10]. In their study, HLA-B8 allele frequen-
cies were estimated as 10.9% for Caucasians, with values
ranging from 1.2% (Asians) to 4.6% (African Americans)
for the other ethnic groups. Although these values cannot
be translated into the skin types of German bone marrow
donors, it is obvious that all ethnic groups having a darker
skin type have significantly lower HLA-B8 allele frequen-
cies than Caucasians. Therefore, an under-representation
of these ethnic groups in stage IV melanoma patients
should lead to an increased, rather than a reduced, HLA-
B8 frequency when compared to the normal population.
Taken together, these arguments do not support the
notion that differences in skin type between the
melanoma patient and control groups account for the
observed reduction in HLA-B8 carrier frequencies.
It should be noted that several independent reports have
already demonstrated a reduction of HLA-B8 and HLA-
B35 in melanoma patients [11-13] or a selective loss of
HLA alleles in metastasis [14]. Furthermore, HLA-B8- and
HLA-B35-restricted melanoma-specific T cell responses
have been identified [15,16]. The recognized epitopes are
derived from tyrosinase, Melan-A/MART-1, gp100,
MAGE-A3/MAGE-A6 and NY-ESO-1 [17-19]; we recently
added a HLA-B35-restricted epitope of the inhibitor of
apoptosis protein survivin to this list [20]. Thus, it is
tempting to speculate that the observed decrease of HLA-
B8 carrier frequencies in advanced melanoma is the result
of an effective immune response directed against specific
TAA-derived epitopes presented by the respective HLA
restriction elements, or, conversely, the lack of such
response in patients not expressing these restriction ele-
ments. However, whether the epitopes already identified
are indeed the targets for the hypothetical, protective
immune response responsible for the observed decrease
in HLA frequencies remains elusive. Such epitopes could
only be defined by quantitative and qualitative compari-
son of the cellular immune responses between patients
with early disease, preferentially the primary tumor, and
Table 2: Comparison of HLA-A and B carrier frequencies between stage IV melanoma patients and healthy bone marrow donors. 
HLA-A and -B carrier frequencies of stage IV melanoma patients (739 HLA-A; 709 HLA-B) and healthy bone marrow donors (13,386) 
were compared using a two sided chi-square test with a 95% confidence interval and sorted according to the absolute difference. 
Results are regarded as significant for p values < 0.01; alleles with significant changes are depicted in bold; results are sorted according 
to the percentage difference. Only alleles with carrier frequencies > 5% are included. Subtypes are only included if more than 89% of 
the corresponding allele was subtyped in the melanoma and bone marrow donor group. OR: odds ratio; ci: confidence interval.
HLA melanoma control difference p sign. OR 95% ci OR
B8 16.22% 20.33% 4.12% 0.0079 * 0.76 0.6184 to 0.9302
B35 15.23% 18.53% 3.29% 0.0273 ns 0.79 0.6409 to 0.9744
B7 27.79% 25.34% 2.45% 0.1452 ns 1.13 0.9575 to 1.342
A9 23.68% 21.42% 2.26% 0.1452 ns 1.14 0.9561 to 1.356
A10 11.23% 13.33% 2.1% 0.1015 ns 0.82 0.6509 to 1.039
A26 5.01% 6.98% 1.97% 0.0393 ns 0.70 0.5015 to 0.9846
B40 11.99% 13.84% 1.85% 0.1624 ns 0.85 0.6728 to 1.070
B60 8.46% 10.32% 1.85% 0.1123 ns 0.80 0.6133 to 1.053
B15 14.1% 15.8% 1.7% 0.2266 ns 0.88 0.7047 to 1.087
A28 6.63% 8.3% 1.67% 0.1076 ns 0.78 0.5834 to 1.055
B16 9.59% 7.94% 1.65% 0.1151 ns 1.23 0.9504 to 1.591
B13 5.64% 6.96% 1.31% 0.1762 ns 0.80 0.5774 to 1.108
A32 5.55% 6.69% 1.14% 0.2232 ns 0.82 0.5939 to 1.132
B12 24.96% 23.83% 1.13% 0.4902 ns 1.06 0.8930 to 1.266
A11 9.34% 10.46% 1.12% 0.3308 ns 0.88 0.6839 to 1.137
A24 18.13% 17.26% 0.88% 0.5401 ns 1.06 0.8761 to 1.287
A3 28.96% 28.1% 0.85% 0.6122 ns 1.04 0.8856 to 1.228
B18 10.58% 9.79% 0.79% 0.4900 ns 1.09 0.8526 to 1.395
A19 22.46% 21.79% 0.67% 0.6671 ns 1.04 0.8705 to 1.242
B44 23.41% 22.78% 0.63% 0.6942 ns 1.04 0.8666 to 1.238
A2 51.42% 51.13% 0.29% 0.8768 ns 1.01 0.8724 to 1.173
A1 28.69% 28.94% 0.25% 0.8825 ns 0.99 0.8385 to 1.163
B51 10.3% 10.54% 0.24% 0.8361 ns 0.97 0.7598 to 1.249
B27 8.89% 8.73% 0.15% 0.8884 ns 1.02 0.7814 to 1.329
A25 5.55% 5.61% 0.06% 0.9429 ns 0.99 0.7151 to 1.366BMC Medicine 2006, 4:5 http://www.biomedcentral.com/1741-7015/4/5
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those with advanced disease; in the latter patients, the
protective responses should be underrepresented.
An alternative explanation for the observed decrease in
HLA frequencies could be the genetic linkage to a tumor
suppressor in the broadest sense. HLA-B8 has been shown
to be linked genetically to HLA-A1 [21]. This linkage is
also obvious in our data set of stage IV melanoma
patients, where 80.8% of the patients carrying HLA-B8 are
also positive for HLA-A1. Although no gene dosage effect
that could translate into a reduced number of
homozygous HLA-B8 carriers in the patient group was
observed (data not shown), the association of the 8.1
ancestral haplotype with autoimmune diseases or distinct
TNF-α or complement alleles might be of special interest,
as this might exert an influence on the anti-tumoral
immune response [22-24]. In the case of TNF-α, the -308A
allele that is linked with 8.1 AH is associated with altered
TNF-α production in vitro [22]. Also, 8.1 AH is character-
ized by a non-functional C4B allele and the lack of the
C4A gene, translating into defective complement function
[25,26]. As the complement cascade is involved in inflam-
mation, the clearance of immune complexes, antibody-
dependent cellular cytotoxicty and other immunologi-
cally relevant processes, a genetic defect in the comple-
ment system may indeed affect both innate and adaptive
immunity. However, the definitive answer to whether
HLA-B8 itself or genetic elements linked to HLA-B8 are
responsible for the observed protective phenotype can
only be elucidated by further studies, including the study
of TNF-α or complement alleles.
Conclusion
Overall, this study suggests a significant decrease of HLA-
B8 carrier frequencies in melanoma patients compared to
healthy donors. This difference, which was observed
when HLA carrier frequencies in advanced cancer patients
were compared with healthy bone marrow donors or
patients with loco-regional disease, supports the hypothe-
sis that protective immune responses may be operational
in a subset of melanoma patients independently of ther-
apy, and that distinct MHC class I restriction elements
seem to be preferentially involved in such responses.
Alternatively, the association of 8.1 AH with genetic ele-
ments such as distinct TNF-α alleles or defective comple-
ment components might result in an altered quality of
immune response, preventing the progression of the dis-
ease. If the observed differences can be verified in a fol-
low-up study, a search for the corresponding T-cell
epitopes and/or the associated genetic elements is indi-
cated and might lead to a new generation of effective
tumor vaccines.
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